OrganOx logo

OrganOx

"Living Organs For Life" Transforming transplantation with the OrganOx metra®. A transportable, automated ex vivo liver perfusion device. The core technology employed by the OrganOx metra® has been in development for over 15 years. During this time both of the founders (Professor Peter Friend and Professor Constantin Coussios) have driven the development of organ preservation and maintenance, formerly at the University of Cambridge and latterly at the University of Oxford. OrganOx Limited was founded in April 2008 as a spin-out from the University of Oxford. Conventional cold preservation involves storage of the liver at 4˚C, using a non-physiological perfusion solution that aims to minimise liver decay. By contrast, warm preservation seeks to re-create an environment that mimics the human body by continuously perfusing at physiological pressures and flows with oxygen-carrying red cells at 37˚C and providing nutrition. The liver is therefore functional during the preservation period, producing bile, metabolizing glucose and maintaining a physiological pH. This enables objective assessment of organ performance prior to transplant, extended preservation times, and the potential use of organs that are presently being discarded.

https://www.organox.com/
51-200 employees

Growth Trajectory

OrganOx is poised for growth through market expansion, product development, and strategic partnerships. The company is expanding its customer base and entering new markets, with a commercial launch planned in Canada and U.S. clinical trials for kidney transplant technology. Their partnership with eGenesis to explore xenotransplantation and the development of new applications for their technology beyond organ transplantation indicate significant growth potential.

Technical Challenges

Ensuring consistent and reliable organ preservation.
Improving organ preservation time.
Improving organ viability assessment.
Functional liver assessment
Monitoring and predicting bile duct viability
Automated control of flows, pressures, temperature and blood gases
Optimizing perfusate chemistry to predict better early allograft function

Tech Stack

Normothermic machine perfusion (NMP)

Team Size

CEO
Chief Medical Officer
Chief Technical Officer
Global CCO/President North America
Chief Financial Officer
Chief HR Officer
EVP Finance and Company Secretary
VP Clinical and Medical Affairs; North America
SVP New Ventures
SVP Product Development & Innovation
SVP Operations
VP Global Regulatory Affairs
VP, Global Head of Quality
SVP Product Engineering

Key Risks

Adoption of new technology in transplant centers may be slow, hindering market penetration.
Ensuring consistent and reliable organ preservation with the OrganOx metra is crucial to maintaining trust and adoption.
Competition from static cold storage, a traditional and less expensive method, could limit market share.
Regulatory hurdles and the need for ongoing compliance with FDA and CE mark requirements pose ongoing challenges.
Potential for data breaches and unauthorized access to personal data, given their commitment to GDPR and other data protection laws, necessitates robust security measures.

Opportunities

Expanding the application of NMP technology to other organs, such as kidneys, could significantly increase the market.
Collaborating with transplant centers and research institutions can accelerate innovation and adoption.
Further development of organ preservation and assessment techniques can improve outcomes and increase the number of transplantable organs.
Exploring xenotransplantation possibilities through partnerships like the one with eGenesis could open up new avenues for addressing organ shortages.
Leveraging their fully automated, easy-to-use, and transportable device to optimize transplant logistics and improve efficiency for transplant centers.
Live Data Stream

Access Our Live VC Funding Database

30,000+ funded startups

tracked in the last 3 months

B2B verified emails

of key decision makers

Growth metrics

Real-time company performance data

Live updates

of new VC funding rounds

Advanced filters

for sophisticated queries

API access

with multiple export formats